Fortress Biotech, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Fortress Biotech's CEO, Lindsay A. Rosenwald, M.D., increased his beneficial ownership to 20.7% of the company's common stock following recent equity grants.
NASDAQ
Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.4% following an annual equity grant.
NASDAQ
Fortress Biotech, Inc. has increased its beneficial ownership in Mustang Bio, Inc. to 8.0% following an annual equity grant and maintains a voting majority through preferred stock.
NASDAQ
Fortress Biotech, Inc. has reported a decrease in its beneficial ownership of Mustang Bio, Inc. common stock, falling below the 5% threshold as of September 29, 2025.
NASDAQ
Fortress Biotech, Inc. has ceased to be a beneficial owner of Checkpoint Therapeutics, Inc. common stock following the latter's merger with a subsidiary of Sun Pharmaceutical Industries, Inc.
NASDAQ
SCHEDULE 13D/A: Fortress Biotech Amends Mustang Bio Stake, Retains Voting Majority Through Preferred Stock
Fortress Biotech, Inc. has filed an Amendment No. 5 to its Schedule 13D, updating its beneficial ownership in Mustang Bio, Inc. to 7.9% and reaffirming its control through Class A preferred stock.
NASDAQ
SCHEDULE 13D/A: Fortress Biotech Solidifies Control and Equity Stake in Avenue Therapeutics with Amended 13D Filing
Fortress Biotech, Inc. has filed an Amendment No. 7 to its Schedule 13D, updating its beneficial ownership in Avenue Therapeutics, Inc. to 10.3% and detailing its continued voting majority through Class A preferred stock and ongoing equity grants.
NASDAQ
SCHEDULE 13D/A: Checkpoint Therapeutics to be Acquired by Sun Pharmaceutical for $4.10 Cash Plus CVR
Checkpoint Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Sun Pharmaceutical Industries, Inc. for $4.10 per share in cash plus one contingent value right, with major shareholder Fortress Biotech, Inc. supporting the transaction.
NASDAQ
SCHEDULE 13D/A: Fortress Biotech Solidifies Majority Voting Control in Mustang Bio with Increased Equity Stake
Fortress Biotech, Inc. has increased its beneficial ownership in Mustang Bio, Inc. to 12.4% of common stock, primarily through equity grants and preferred stock, solidifying its majority voting control.
NASDAQ
SCHEDULE 13D/A: Fortress Biotech Boosts Stake in Checkpoint Therapeutics to 13.5% Through Equity Grants, Solidifying Control
Fortress Biotech, Inc. has increased its beneficial ownership in Checkpoint Therapeutics, Inc. to 13.5% of outstanding common stock, primarily through recent equity grants, reinforcing its significant voting control.
NASDAQ
SCHEDULE 13D/A: Fortress Biotech Increases Stake in Avenue Therapeutics, Maintains Voting Majority Through Preferred Stock
Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.8% through equity grants, solidifying its control via Class A preferred stock.